| Commissioners raise questions about new smoking proposal
If a law enforcement official sees an adult smoking in a car where children are present, all this does is give the police the authority to take action: Pull the idiot over, give them a well-deserved lecture and issue a citation. Are you actually arguing that they'd rather see a child abused than give law enforcement officials the authority to stop that abuse if they see it happening? .
dear prudence: Advice on manners and morals.
Get "Dear Prudence" delivered to your inbox each week; click here to sign up. Please send your questions for publication to . (Questions may be edited.) Dear Prudence,
I have been dating this guy for about three months. When we first met, I was struck by his gentleness and kindness. The sex is great. I can express myself, all my quirky idiosyncrasies included, and not fear judgment or ridicule. He understands me and accepts me as I am. Which is why I'm having such a hard time with this dilemma: I've never dated anyone so sensitive before. He has his bad days, as we all do, but his bad days make him cry. His mood spirals down into an abyss of self-hatred and emotional despair. I try to talk him out of it, and often I'm successful. He says that just seeing me and holding me boosts his mood considerably.
Yaupon Therapeutics Closes $14.5 Million Financing
RADNOR, Pa., Nov. 26 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company developing small molecule pharmaceuticals, today announced the closing of a $14.5 million round of venture capital financing. The Series C financing will expand the continued advancement of Yaupon's multiple clinical programs. The venture capital financing was led by Vivo Ventures with additional funding from Palo Alto Investors, LLC and private investors. The financing will support the ongoing clinical development program for Clearazide(TM), a topically delivered cytotoxic agent for the treatment of cutaneous T-cell lymphoma (CTCL) that is currently in pivotal clinical studies. The funding will also position Yaupon to pursue neuropsychiatric indications such as Attention Deficit Disorder (ADD) and Tourette's syndrome for Lobeline, a dopamine modulating agent that is currently in phase 2 trials for methamphetamine addiction.
|
